Tofogliflozin composition

A technology of toggliflozin and composition, which is applied in the field of toggliflozin tablet composition, can solve the problems of high related substances, low dissolution rate of preparations, etc. Effect

Inactive Publication Date: 2018-03-20
WEIHAI GUANBIAO INFORMATION TECH
3 Cites 1 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0007] The object of the present invention is to provide a topagliflozin composition, which solves the problem that the disso...
View more

Abstract

The invention relates to a torgliflozin tablet composition and belongs to the technical field of pharmaceutical preparations. The torgliflozin tablet composition in a unit dose comprises 5 mg of torgliflozin, 65 to 80 mg of lactose, 0.8 to 1.5 mg of sodium lauryl sulfate, 10 to 20 mg of calcium sulfate, 8-15mg of fumed silica, 8-16mg of beta-cyclodextrin, 4-8mg of povidone K30, 4-8mg of cross-linked povidone and 1-1.5mg of magnesium stearate. The stable torgliflozin tablet composition has excellent dissolution rate, and the dissolution rate and the content of related substances are stable during the effective period. The problems of decline in the dissolution rate and raise of the content of the related substances in the tablet storage process in the prior art can be solved.

Application Domain

Metabolism disorderInorganic non-active ingredients +3

Technology Topic

Magnesium stearatePharmaceutical formulation +10

Examples

  • Experimental program(3)
  • Comparison scheme(2)
  • Effect test(2)

Example Embodiment

[0023] Example 1. Togliflozin 5g, lactose 80g, sodium lauryl sulfate 8g, calcium sulfate 10g, fumed silica 8g, β-cyclodextrin 8g, povidone K30 4g, crospovidone 4g, Magnesium stearate 1g, 1000 tablets were prepared according to the preparation method described in the technical scheme.

Example Embodiment

[0024] Example 2. Togliflozin 5g, lactose 65g, sodium lauryl sulfate 1.5g, calcium sulfate 20g, fumed silica 15g, β-cyclodextrin 16g, povidone K30 8g, crospovidone 8g , 1.5g magnesium stearate, 1000 tablets were prepared according to the preparation method described in the technical scheme.

Example Embodiment

[0025] Example 3. Togliflozin 5g, lactose 70g, sodium lauryl sulfate 1.2g, calcium sulfate 15g, fumed silica 10g, β-cyclodextrin 12g, povidone K30 6g, crospovidone 6g , 1.3g magnesium stearate, 1000 tablets were prepared according to the preparation method described in the technical scheme.

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.

Similar technology patents

Linezolid tablets in stable crystal form and preparation method thereof

ActiveCN102885788AGood compressibilityGood dissolution rate
Owner:CHONGQING HUAPONT PHARMA

Escketamine hydrochloride tablet and preparation method thereof

PendingCN114191397AGood dissolution rateImprove stability
Owner:BEIJING WANQUAN SUNSHINE MEDICAL TECH CO LTD

Azithromycin granule and preparation method thereof

InactiveCN106265529AGood dissolution ratehigh utility value
Owner:SHANGHAI HUA SURNAME PHARMA

Classification and recommendation of technical efficacy words

  • Good dissolution rate

Linezolid tablets in stable crystal form and preparation method thereof

ActiveCN102885788AGood compressibilityGood dissolution rate
Owner:CHONGQING HUAPONT PHARMA

Escketamine hydrochloride tablet and preparation method thereof

PendingCN114191397AGood dissolution rateImprove stability
Owner:BEIJING WANQUAN SUNSHINE MEDICAL TECH CO LTD

Azithromycin granule and preparation method thereof

InactiveCN106265529AGood dissolution ratehigh utility value
Owner:SHANGHAI HUA SURNAME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products